Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 63.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,142 shares of the biotechnology company's stock after buying an additional 4,338 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Ascendis Pharma A/S were worth $1,664,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ASND. Avoro Capital Advisors LLC increased its stake in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company's stock worth $616,050,000 after buying an additional 44,580 shares during the period. Capital International Investors grew its stake in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock valued at $331,261,000 after buying an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after buying an additional 336,976 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company's stock valued at $233,348,000 after buying an additional 93,185 shares during the period.

Analyst Ratings Changes

Several analysts have issued reports on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a research report on Wednesday, October 23rd. Oppenheimer reaffirmed an "outperform" rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Evercore ISI raised their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday, September 17th. Citigroup boosted their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Finally, Bank of America raised their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $195.92.

Ascendis Pharma A/S Stock Down 2.1 %

Shares of NASDAQ:ASND traded down $2.67 during trading on Tuesday, hitting $126.77. 317,434 shares of the company traded hands, compared to its average volume of 445,644. The stock has a market capitalization of $7.38 billion, a price-to-earnings ratio of -13.33 and a beta of 0.64. Ascendis Pharma A/S has a one year low of $86.54 and a one year high of $161.00. The business's fifty day moving average is $134.56 and its 200-day moving average is $134.11.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, analysts forecast that Ascendis Pharma A/S will post -7.2 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.